Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Université de Sherbrooke

$25,000.00

Synthesis of TRIOZAN-Peptide Conjugates as Blood-Brain Transient Drug Nanovector

EF 2017-18

Résumé
In spite of considerable advancement in cancer chemotherapy, the survival rate in brain cancer patients isextremely limited mainly due to the blood-brain barrier (BBB) which prevents the transmission of drug fromblood circulation into the brain parenchyma. The present research proposal is based on the conjugation ofTRIOZANTM, as a nanomedicine delivery platform under proprietary of Ovensa Inc., with B1R agonist ligand.The permeability of B1R-functionalized TRIOZANTM will be evaluated via the measurement of its bindingaffinity to the endothelial cell receptors. Developed technology will be transferred to Ovensa Inc. as a key stepin developing of blood-brain-transient drug delivery platform.
Programme
Engage Grants Program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
511143-2017
Name nom
Dory, Yves
Department département
Chimie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3754
Research subject group en
Polymer chemistry
Research subject group fr
Chimie des polymères
Research subject en
Biopolymers
Research subject fr
Biopolymères
Partie
1
Nb partie
1
Application title
Synthesis of TRIOZAN-Peptide Conjugates as Blood-Brain Transient Drug Nanovector
Keyword
NSERC
Application summary
In spite of considerable advancement in cancer chemotherapy, the survival rate in brain cancer patients isextremely limited mainly due to the blood-brain barrier (BBB) which prevents the transmission of drug fromblood circulation into the brain parenchyma. The present research proposal is based on the conjugation ofTRIOZANTM, as a nanomedicine delivery platform under proprietary of Ovensa Inc., with B1R agonist ligand.The permeability of B1R-functionalized TRIOZANTM will be evaluated via the measurement of its bindingaffinity to the endothelial cell receptors. Developed technology will be transferred to Ovensa Inc. as a key stepin developing of blood-brain-transient drug delivery platform.